Return to Vaccination News Home Page
Subscribe to the Vaccination NewsLetter
View past & current Scandals (columns by Sandy Mintz)
Search This Site using keywords
Note: SV40 is thought to now have spread beyond the original polio vaccine exposure. For more on SV40 and cancer, click here. - SM
http://www3.interscience.wiley.com/cgi-bin/abstract/104529612/START
|
|
|
|
|
|
|
|
|
| Article Abstract |
 |
 |
 |
 |
 |
Online ISSN: 1097-0215 Print ISSN: 0020-7136 Copyright © 2003 Wiley-Liss, Inc. |
|
Epidemiology
| Childhood exposure to simian
virus 40-contaminated poliovirus vaccine and risk of AIDS-associated
non-Hodgkin's lymphoma |
Eric A. Engels 1 * , Leonard H.
Rodman 1, Morten Frisch 2, James J. Goedert 1,
Robert J. Biggar 1 |
| 1Viral Epidemiology Branch,
Division of Cancer Epidemiology and Genetics, National Cancer
Institute, Rockville, MD, USA 2Department of Epidemiology Research, Danish Epidemiology Science Center, Statens Serum Institut, Copenhagen, Denmark |
| email: Eric A. Engels (engelse@exchange.nih.gov) |
*Correspondence to Eric A. Engels, Viral Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd., EPS 8010, Rockville, MD 20892, USA
Fax:
+301-402-0817
| Keywords |
| Simian virus 40 • acquired immunodeficiency syndrome (AIDS) • human immunodeficiency virus (HIV) • non-Hodgkin's lymphoma • vaccine |
| Abstract |
| Persons with acquired immunodeficiency syndrome (AIDS) have increased risk for non-Hodgkin's lymphoma (NHL). Recent studies have reported the detection of DNA sequences from simian virus 40 (SV40), a macaque polyomavirus that contaminated early poliovirus vaccines, in a large proportion of AIDS-associated NHLs. To examine the association between SV40 exposure and NHL risk, we analyzed data from a U.S. registry-based cohort study of persons with AIDS (1980-96). We calculated NHL incidence in persons born in 1958-61 (exposed to SV40-contaminated poliovirus vaccine as children, n = 39,468) and in 1964-67 (born after vaccines were cleared of SV40 and thus unexposed, n = 17,340). Among persons with AIDS, NHL incidence was 11.7 per 1,000 person-years in SV40-exposed individuals (616 NHL cases) and 10.1 per 1,000 person-years in SV40-unexposed individuals (230 cases; unadjusted relative risk 1.15, 95% CI 0.99-1.34, p = 0.06). Because of differences in cohorts' birth years and the evolving demographics of the AIDS epidemic, SV40-exposed subjects were older at AIDS onset than unexposed subjects (mean age 32.0 vs. 27.2 years, p < 0.0001), and the cohorts differed by sex (p < 0.0001) and ethnic group (p < 0.0001). Since NHL incidence was relatively high among whites (p < 0.0001) and homosexual males (p < 0.0001) and increased with age (p = 0.09), comparisons required adjustments for these factors. After adjustment, SV40 exposure was not associated with NHL incidence (adjusted relative risk 0.97, 95% CI 0.79-1.20, p = 0.80). We conclude that childhood exposure to SV40 through receipt of contaminated poliovirus vaccine was not associated with increased risk for AIDS-associated NHL. Our findings do not support a role for SV40 in lymphomagenesis among immunosuppressed persons. © 2003 Wiley-Liss, Inc. |
Received: 14 November 2002; Revised: 25 February 2003; Accepted: 28 February 2003
| Digital Object Identifier (DOI) |
10.1002/ijc.11211 About DOI
| References are available in the Enhanced Abstract |
Additional Information
 |
[Wiley InterScience Home Page] [Personal Home Page] [Journal Finder] [Book Finder] [Search Wiley InterScience] [Reference Works] [Help] [Contact Us][Logout]
Wiley InterScience is a member of CrossRef
Copyright © 1999-2003 by
John Wiley & Sons, Inc. All rights reserved.
Return to Vaccination News Home Page
DISCLAIMER: All information, data, and material contained, presented, or provided here is for general information purposes only and is not to be construed as reflecting the knowledge or opinions of the publisher, and is not to be construed or intended as providing medical or legal advice. The decision whether or not to vaccinate is an important and complex issue and should be made by you, and you alone, in consultation with your health care provider.
